Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

Rhea-AI Summary

Anavex Life Sciences (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing treatments for neurological disorders, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.

CEO Christopher U. Missling, PhD, will deliver a presentation on September 9, 2025, at 1:00 p.m. ET at the Lotte New York Palace. The company will provide updates on its innovative treatments for conditions including Alzheimer's disease, Parkinson's disease, and Rett syndrome. Investors can access the presentation through a live audio webcast on the company's website.

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, announced today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright 27^th Annual Global Investment Conference, being held September 8-10, 2025 in New York City.

The presentation will take place on Tuesday, September 9, 2025, at 1:00 p.m. ET at the Lotte New York Palace in New York, NY. An audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. A replay of the session will be available later that day.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com

Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com

FAQ

When and where will Anavex Life Sciences (AVXL) present at the H.C. Wainwright Conference 2025?

Anavex will present on Tuesday, September 9, 2025, at 1:00 p.m. ET at the Lotte New York Palace in New York City.

How can investors access Anavex's (AVXL) presentation at the H.C. Wainwright Conference?

Investors can access the presentation through an audio webcast available in the Investors section of Anavex's website at www.anavex.com. A replay will be available later that day.

What therapeutic areas does Anavex Life Sciences (AVXL) focus on?

Anavex focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental disorders, neurodegenerative diseases, Rett syndrome, and other CNS disorders.

Who will be presenting for Anavex (AVXL) at the H.C. Wainwright Conference?

Christopher U. Missling, PhD, the President and Chief Executive Officer of Anavex, will present at the conference.